Ebru TÜRKOĞLU, Cemile SÖNMEZ, FEHİME ESRA ÖZER, Nilay ÇÖPLÜ, Zafer KURUGÖL

Low pertussis antibody levels in maternal and umbilical cord blood samples in Turkey

Pertussis continues to cause significant mortality and morbidity in many countries despite high vaccine coverage, especially among young infants. The aim of the study was to determine pertussis antibody levels in paired maternal and cord blood samples, to evaluate the placental transfer of these antibodies, and to assess whether newborn infants have adequate antibody levels against pertussis. Antibody titers to pertussis toxin (anti-PT) and filamentous hemagglutinin (anti-FHA) were measured by in-house enzyme linked immunosorbent assay (ELISA) in 251 paired maternal delivery and cord blood samples. Geometric mean concentrations (GMCs) of pertussis antibodies and cord:maternal GMC ratios were calculated. GMCs of maternal anti-PT and anti-FHA antibodies at delivery were 4.12 and 9.89 EU/ml, respectively. Cord GMCs were 133% and 131% of maternal delivery values for PT and FHA, respectively; demonstrating effective placental transfer. However, cord pertussis antibodies were at a low concentration; 5.49 EU/ml for PT and 12.73 EU/ml for FHA. Only 34.6% of infants had protective anti-PT levels (≥10 EU/ml) at birth. Anti-pertussis antibody concentrations were extremely low in pregnant women in Turkey where childhood pertussis vaccination coverage has been high for a long time. Despite effective placental antibody transfer, umbilical cord pertussis antibody concentrations are similarly low. A majority of young infants are vulnerable to pertussis infection until the onset of primary vaccinations. These data support the need for pertussis vaccination during pregnancy to prevent infant infection in Turkey.

PDF

___

Subaiya S, Dumolard L, Lydon P, Gacic-Dobo M, Eggers R, Conklin L. Global Routine Vaccination Coverage, 2014. MMWR Morb Mortal Wkly Rep 2015; 64: 1252- 1255.

Pertussis vaccines: WHO position paper, August 2015. Wkly. Epidemiol Rec 2015; 90: 433-460.

Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 2003; 22: 628-634.

Forsyth K, Plotkin S, Tan T, Wirsing von König CH. Strategies to decrease pertussis transmission to infants. Pediatrics 2015; 135: 1475-1482.

Juretzko P, von Kries R, Hermann M, Wirsing von König CH, Weil J, Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis 2002; 35: 162-167.

Quinn HE, Snelling TL, Macartney KK, McIntyre PB. Duration of protection after first dose of acellular pertussis vaccine in infants. Pediatrics 2014; 133: e513-e519.

Van Rie A, Wendelboe AM, Englund JA. Role of maternal antibodies in infants. Pediatr Infect Dis J 2005; 24 (5 Suppl): 62-65.

Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16: 1901-1906.

Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907-1916.

Taranger J, Trollfors B, Lagergard T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000; 181:1010-1013.

Miller JJ, Harold KF, Ryan ML, Silverberg RJ, Lew E. Immunization against pertussis during the first four months of life. Pediatrics 1949; 4: 468-478.

Bigham M, Konrad S, Van Buynder P, et al. Low pertussis toxin antibody levels in two regional cohorts of Canadian pregnant women. Vaccine 2014; 32: 6493- 6498.

Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004; 190: 335-340.

Fallo A, Manonelles G, Hozbor D, et al. Pertussis seroprevalence in adults, post-partum women and umbilical cord blood. Arch Argent Pediatr 2014; 112: 315-322.

Ercan TE, Sonmez C, Vural M, Erginoz E, Torunoğlu MA, Perk Y. Seroprevalance of pertussis antibodies in maternal and cord blood of preterm and term infants. Vaccine 2013; 31: 4172-4176.

Gonik B, Puder KS, Gonik N, Kruger M. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. Infect Dis Obstet Gynecol 2005; 13: 59-61.

Kurugöl Z. Boğmaca aşısı ve sorunlar. ANKEM Dergisi 2011; 25: 212-217.

Çöplü N, Esen B, Kurtoğlu D, Gözalan A, Miyamura K, Yoshida I. Standardization of an in-house ELISA for pertussis serology and its application in a seroepidemiological study. Mikrobiyol Bul 2005; 39: 281-289.

Giammanco A, Chiarini A, Maple PA, et al. European Sero-Epidemiology Network: standardization of the assay results for pertussis. Vaccine 2003; 22: 112-120.

Baughman AL, Bisgard KM, Edwards KM, et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 2004; 11: 1045-1053.

Plans P, Jansà J, Doshi N, Harrison TG, Plasència A. Prevalence of pertussis antibodies in umbilical cord blood samples in Catalonia, Spain. Pediatr Infect Dis J 2008; 27: 1023-1025.

Heininger U, Riffelmann M, Leineweber B, Wirsing von Koenig CH. Maternally derived antibodies against Bordetella pertussis antigens pertussis toxin and filamentous hemagglutinin in preterm and full term newborns. Pediatr Infect Dis J 2009; 28: 443-445.

de Voer RM, van der Klis FR, Nooitgedagt JE, et al. Seroprevalence and placental pransportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis 2009; 49: 58-64.

Shakib JH, Ralston S, Raissy HH, Stoddard GJ, Edwards KM, Byington CL. Pertussis antibodies in postpartum women and their newborns. J Perinatol 2010; 30: 93- 97.

Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011; 204: e1-e5.

Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011; 30: 608-610.

Vilajeliu A, Goncé A, López M, et al; PERTU Working Group. Combined tetanus-diphtheria and pertussis vaccine during pregnancy: transfer of maternal pertussis antibodies to the newborn. Vaccine 2015; 33: 1056- 1062.

Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: A randomized clinical trial. JAMA 2014; 311:1760-1769.

Walls T, Graham P, Petousis-Harris H, Hill L, Austin N. Infant outcomes after exposure to Tdap vaccine in pregnancy: An observational study. BMJ Open 2016; 6: e009536.

Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ 2014; 349: g4219.

Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014; 384: 1521-1528.

Centers for Disease Control Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine(Tdap) in pregnant women—Advisory Committee on Immunization Practices(ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 131-135.